Norgine and Jubilant Biosys Ltd., a subsidiary of Jubilant Life Sciences, have entered into a discovery collaboration to provide a platform for Norgine to develop multiple targets using Jubilant’s drug discovery platform targeting gastrointestinal diseases. The initial term of the agreement is three years. Jubilant will deliver preclinical candidates and Norgine will have rights to further development and commercialization.   Sri Mosur, president and chief executive officer, Global Drug Discover...